Compare Credo Technology Group Holding Ltd (CRDO) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Credo Technology Group Holding Ltd trades at $216.55 (market cap $39.82B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Credo Technology Group Holding Ltd is far larger — about 3.2× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| CRDO | HALO | |
|---|---|---|
Market Cap | $39.82B | $12.58B |
Volume | 9,451,558 | 2,179,278 |
Sector | Technology | Health |
52-Week High | $302.52 | $115.22 |
52-Week Low | $87.81 | $61.63 |
Typical Hold Time | 22 Days | 1 Days |
Enterprise Value | $39.08B | $14.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $216.55, down 1.57% on the day, but maintains strong bullish momentum with triple-digit revenue growth driven by AI infrastructure demand. The stock shows robust fundamentals with 33.83% net margins and consistent earnings beats, though valuation metrics remain elevated with a P/E of 74.6. Technical indicators suggest bullish momentum with support at $204 and resistance at $222.
Outlook remains positive given explosive AI-driven growth and strong analyst support (87.5% buy ratings), but premium valuation and customer concentration present execution risks. The consensus price target of $267.33 implies 23% upside potential from current levels, supported by expanding optical product offerings and hyperscaler relationships.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
